A 28-year-old woman from rural Rajasthan presents with fatigue, dyspnea on exertion, and glossitis. Her hemoglobin is 7.2 g/dL with microcytic hypochromic indices. Serum ferritin is 8 ng/mL, serum iron is 35 µg/dL, and TIBC is 420 µg/dL. All of the following interventions are appropriate in her management EXCEPT:

Explanation

## Iron Deficiency Anemia Management: Oral vs. Parenteral Iron ### Clinical Context The patient presents with classic iron deficiency anemia (IDA): - Microcytic hypochromic anemia (Hb 7.2 g/dL) - Low ferritin (8 ng/mL, normal >30 ng/mL) - Low serum iron (35 µg/dL, normal 50–170 µg/dL) - Elevated TIBC (420 µg/dL, normal 250–425 µg/dL) — indicates iron-deficient state ### Correct Answer Analysis **Parenteral iron dextran as a single 1000 mg IV infusion** — This is NOT appropriate and is the exception. **Key Point:** While parenteral iron is indicated in specific scenarios (malabsorption, intolerance to oral iron, inflammatory bowel disease, chronic kidney disease on hemodialysis), it is NOT the first-line approach for uncomplicated IDA in an otherwise healthy woman with intact GI absorption. Moreover, a single 1000 mg bolus carries unnecessary risk of iron overload and anaphylaxis. Parenteral iron is reserved for cases where oral iron cannot be used or has failed. ### Why the Other Statements Are Correct | Intervention | Appropriateness | Rationale | |--------------|-----------------|----------| | Oral ferrous sulfate 200 mg + ascorbic acid | ✓ CORRECT | First-line therapy for IDA. Ferrous salts are preferred (better absorption than ferric). Vitamin C reduces Fe³⁺ to Fe²⁺ and maintains acidic pH, enhancing absorption. Expect Hb rise of 1–2 g/dL per month. | | Dietary counseling: heme iron sources | ✓ CORRECT | Heme iron (from meat, poultry, fish) has 15–35% bioavailability vs. 2–20% for non-heme iron. Dietary modification is a sustainable adjunct to supplementation. | | Investigation for GI bleeding & menstrual loss | ✓ CORRECT | Identifying the SOURCE of iron loss is essential. In a woman of reproductive age, menorrhagia is the most common cause; GI bleeding must be excluded in men and post-menopausal women. | ### High-Yield Clinical Pearls **Mnemonic: ORAL iron is FIRST-LINE for IDA — Use PARENTERAL only when oral fails, cannot be tolerated, or absorption is impaired (GI disease, post-bariatric surgery).** **Clinical Pearl:** Oral iron side effects (nausea, constipation, abdominal discomfort) occur in 10–20% of patients. If intolerance develops, reduce dose, take with food (though this slightly reduces absorption), or switch to ferrous fumarate or gluconate. Parenteral iron should only be considered after documented oral intolerance. **Tip:** Expected response to oral iron therapy: - Reticulocytosis within 3–5 days - Hemoglobin rise of 1–2 g/dL per month - Normalization of Hb by 2–3 months - Continue iron for 3–6 months after Hb normalizes to replete iron stores (ferritin >50 ng/mL).